<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="symptoms ranging from mild to life-threatening. The vast majority of" exact="influenza" post="virus infections in humans are observed during seasonal epidemics"/>
 <result pre="occasional pandemics. Given the substantial public health burden associated with" exact="influenza" post="virus infection, yearly vaccination is recommended for protection against"/>
 <result pre="virus infection, yearly vaccination is recommended for protection against seasonal" exact="influenza" post="viruses. Despite vigilant surveillance for new variants and careful"/>
 <result pre="status. In order to broaden the protection afforded by seasonal" exact="influenza" post="vaccines, the National Institute of Allergy and Infectious Diseases"/>
 <result pre="Infectious Diseases (NIAID) has deemed the development of a universal" exact="influenza" post="virus vaccine to be a priority in influenza virus"/>
 <result pre="a universal influenza virus vaccine to be a priority in" exact="influenza" post="virus vaccine research. This universal vaccine would provide protection"/>
 <result pre="vaccine research. This universal vaccine would provide protection against all" exact="influenza" post="virus strains, eliminating the need for the yearly reformulations"/>
 <result pre="strains, eliminating the need for the yearly reformulations of seasonal" exact="influenza" post="vaccines. In addition to universal influenza vaccine efforts, substantial"/>
 <result pre="yearly reformulations of seasonal influenza vaccines. In addition to universal" exact="influenza" post="vaccine efforts, substantial progress has been made in developing"/>
 <result pre="vaccine efforts, substantial progress has been made in developing novel" exact="influenza" post="virus therapeutics that utilize broadly neutralizing antibodies to provide"/>
 <result pre="therapeutics that utilize broadly neutralizing antibodies to provide protection against" exact="influenza" post="virus infection and to mitigate disease outcomes during infection."/>
 <result pre="review, we discuss various approaches toward the goal of improving" exact="influenza" post="virus vaccine efficacy through a universal influenza virus vaccine."/>
 <result pre="goal of improving influenza virus vaccine efficacy through a universal" exact="influenza" post="virus vaccine. We also address the novel methods of"/>
 <result pre="of discovery and utilization of broadly neutralizing antibodies to improve" exact="influenza" post="disease outcomes. influenza universal influenza vaccine vaccine influenza therapeutics"/>
 <result pre="utilization of broadly neutralizing antibodies to improve influenza disease outcomes." exact="influenza" post="universal influenza vaccine vaccine influenza therapeutics immunization Funding NIH"/>
 <result pre="broadly neutralizing antibodies to improve influenza disease outcomes. influenza universal" exact="influenza" post="vaccine vaccine influenza therapeutics immunization Funding NIH Molecular and"/>
 <result pre="to improve influenza disease outcomes. influenza universal influenza vaccine vaccine" exact="influenza" post="therapeutics immunization Funding NIH Molecular and Cellular Biology NIAID10.13039/100000060R01AI123359R01AI127775"/>
 <result pre="burden worldwide, causing yearly epidemics and occasional pandemics. Infection with" exact="influenza" post="virus causes acute upper respiratory disease in humans that"/>
 <result pre="and occasional pandemics. Infection with influenza virus causes acute upper" exact="respiratory disease" post="in humans that can potentially lead to hospitalization or"/>
 <result pre="death. In addition to the morbidity and mortality associated with" exact="influenza" post="virus infection, the yearly economic burden of influenza virus"/>
 <result pre="associated with influenza virus infection, the yearly economic burden of" exact="influenza" post="virus infections in the United States is estimated to"/>
 <result pre="billion (Putri et al., 2018). Given the considerable impact of" exact="influenza" post="virus infection in communities worldwide, significant attention has been"/>
 <result pre="in communities worldwide, significant attention has been focused on preventing" exact="influenza" post="virus infection and spread of the virus through vaccination"/>
 <result pre="characterized by segmented, negative sense, single-stranded RNA genome. Of the" exact="influenza" post="virus types, influenza A and B are the only"/>
 <result pre="negative sense, single-stranded RNA genome. Of the influenza virus types," exact="influenza" post="A and B are the only types that are"/>
 <result pre="known to cause disease in humans. In addition to humans," exact="influenza" post="A viruses can infect a broad variety of species"/>
 <result pre="pigs, horses, and birds (Webster et al., 1995). In nature," exact="influenza" post="A viruses are maintained in water fowls, which are"/>
 <result pre="maintained in water fowls, which are the main reservoir for" exact="influenza" post="A (Webster et al., 1995). Influenza A viruses can"/>
 <result pre="hemagglutinin (HA) and neuraminidase (NA) (Fields et al., 2013). For" exact="influenza" post="A viruses, there are 18 known HA subtypes that"/>
 <result pre="of viruses that are derived from a common ancestor. Unlike" exact="influenza" post="A viruses, the diversity of influenza B viruses is"/>
 <result pre="a common ancestor. Unlike influenza A viruses, the diversity of" exact="influenza" post="B viruses is limited and is categorized into two"/>
 <result pre="and B/Victoria (Rota et al., 1990). Despite the limited diversity," exact="influenza" post="B viruses evolve to escape immunity and remain in"/>
 <result pre="in circulation in humans; thus, necessitating yearly updates of the" exact="influenza" post="B virus strains included in the seasonal vaccine. Immunological"/>
 <result pre="(Fields et al., 2013). The initial innate immune responses against" exact="influenza" post="virus infection are activated by the sensing of viral"/>
 <result pre="innate sensing pathways also contribute to robust innate responses against" exact="influenza" post="virus infection (Iwasaki and Pillai, 2014). Ultimately, the activation"/>
 <result pre="mice demonstrate the importance of T-cell responses in clearing primary" exact="influenza" post="virus infection and mounting robust recall responses in subsequent"/>
 <result pre="et al., 2013). The importance of CD8+ T cells during" exact="influenza" post="virus infection was further highlighted in adoptive transfer experiments"/>
 <result pre="also been shown to have an important role in clearing" exact="influenza" post="infection, with the lack of CD4+ T cells correlating"/>
 <result pre="T cells in mice was associated with greater protection during" exact="influenza" post="infection (McKinstry et al., 2012). The mucosal antibody response"/>
 <result pre="viral infection. The three main immunoglobulin (Ig) isotypes induced during" exact="influenza" post="infection are IgG, IgA, and IgM. Secretory IgA antibodies"/>
 <result pre="during infection and can act as an indicator of acute" exact="influenza" post="infection (Rothbarth et al., 1999). Additionally, secretory IgA antibodies"/>
 <result pre="upper respiratory tract while also providing cross-reactive protection against different" exact="influenza" post="virus strains (Tamura et al., 1990; Asahi et al.,"/>
 <result pre="al., 1990). Current Seasonal Influenza Vaccines The composition of seasonal" exact="influenza" post="virus vaccines is based on the strains currently propagating"/>
 <result pre="currently propagating in the human population. Presently, there are two" exact="influenza" post="A virus strains (H1N1 and H3N2) and two influenza"/>
 <result pre="two influenza A virus strains (H1N1 and H3N2) and two" exact="influenza" post="B virus lineages circulating in humans, with only one"/>
 <result pre="influenza B virus lineages circulating in humans, with only one" exact="influenza" post="B strain from each type circulating as the predominant"/>
 <result pre="strain from each type circulating as the predominant strain during" exact="influenza" post="season. However, as it is impossible to predict the"/>
 <result pre="for a given season, the majority of the current seasonal" exact="influenza" post="vaccines are composed of all four strains. The selection"/>
 <result pre="vaccines are composed of all four strains. The selection of" exact="influenza" post="strains for incorporation into seasonal vaccines is based on"/>
 <result pre="vaccines is based on surveillance of circulating strains by WHO" exact="influenza" post="centers as well as on an assessment of which"/>
 <result pre="and distributed (Gerdil, 2003). There are four types of seasonal" exact="influenza" post="virus vaccines currently licensed for use in humans: inactivated,"/>
 <result pre="recombinant protein, and cell-based vaccines. A vast majority of the" exact="influenza" post="virus vaccines administered in humans are split inactivated vaccines,"/>
 <result pre="(Clements et al., 1986). Similar to inactivated vaccines, live attenuated" exact="influenza" post="vaccines (LAIVs) are grown in embryonated eggs. LAIV strains"/>
 <result pre="genetics approach to incorporate HA and NA genes from circulating" exact="influenza" post="strains into a cold-adapted, attenuated influenza virus backbone (Sridhar"/>
 <result pre="NA genes from circulating influenza strains into a cold-adapted, attenuated" exact="influenza" post="virus backbone (Sridhar et al., 2015). Cold adaption of"/>
 <result pre="individuals with egg allergies. Recombinant protein vaccines and cell culture-based" exact="influenza" post="vaccines have been developed to overcome limitations of egg-based"/>
 <result pre="(FDA). Flublok® still contains HA protein antigens representing the selected" exact="influenza" post="strains for the current season, but it is produced"/>
 <result pre="Challenges for Current Seasonal Vaccines Yearly vaccination with split, inactivated" exact="influenza" post="vaccines is still one of the most popular and"/>
 <result pre="the most popular and efficient means of protection against seasonal" exact="influenza" post="viruses. Prior to 2012, influenza vaccines were trivalent and"/>
 <result pre="means of protection against seasonal influenza viruses. Prior to 2012," exact="influenza" post="vaccines were trivalent and contained only one influenza B"/>
 <result pre="to 2012, influenza vaccines were trivalent and contained only one" exact="influenza" post="B virus in the vaccine. This often resulted in"/>
 <result pre="in the vaccine. This often resulted in inadequate protection against" exact="influenza" post="B virus, due to mismatches between the circulating influenza"/>
 <result pre="against influenza B virus, due to mismatches between the circulating" exact="influenza" post="B virus lineage and the influenza B virus lineage"/>
 <result pre="mismatches between the circulating influenza B virus lineage and the" exact="influenza" post="B virus lineage chosen for vaccine incorporation (Tisa et"/>
 <result pre="vaccine incorporation (Tisa et al., 2016). To avoid issues with" exact="influenza" post="B virus lineage mismatches, a quadrivalent inactivated vaccine that"/>
 <result pre="virus lineage mismatches, a quadrivalent inactivated vaccine that contains both" exact="influenza" post="B virus lineages was developed (Tisa et al., 2016)."/>
 <result pre="(Tisa et al., 2016). Despite these improvements to the seasonal" exact="influenza" post="virus vaccines, the effectiveness of seasonal influenza vaccines can"/>
 <result pre="to the seasonal influenza virus vaccines, the effectiveness of seasonal" exact="influenza" post="vaccines can vary greatly, depending on how closely the"/>
 <result pre="2007). Furthermore, yearly vaccines do not provide protection against novel" exact="influenza" post="virus strains introduced from zoonotic reservoirs, causing significant morbidity"/>
 <result pre="population. The types of immune responses elicited by different seasonal" exact="influenza" post="vaccines also impact the degree and the longevity of"/>
 <result pre="responses; however, this vaccine failed to provide adequate protection against" exact="influenza" post="A(H1N1)pdm09 during the 2013–2014 and 2015–2016 seasons (Grohskopf et"/>
 <result pre="al., 2016). Currently, the quadrivalent LAIV has incorporated a new" exact="influenza" post="A(H1N1)pdm09-like virus that provides better protection and is recommended"/>
 <result pre="to induction of effective immunity. A vast majority of seasonal" exact="influenza" post="vaccines are manufactured in eggs. Occasionally, during vaccine production,"/>
 <result pre="different vaccination approaches have the potential for improving upon yearly" exact="influenza" post="virus vaccines as well as in the development of"/>
 <result pre="virus vaccines as well as in the development of universal" exact="influenza" post="virus vaccines. An additional consideration for seasonal influenza vaccines"/>
 <result pre="of universal influenza virus vaccines. An additional consideration for seasonal" exact="influenza" post="vaccines is the ability to provide protection among older"/>
 <result pre="among older adults, who are often at higher risk for" exact="influenza" post="infection. The usual dosage of 15 μg HA antigen"/>
 <result pre="split-virus vaccine that contains 60 μg of HA for each" exact="influenza" post="strain included in the vaccine (Robertson et al., 2016)."/>
 <result pre="et al., 2016). The most significant challenge for the seasonal" exact="influenza" post="vaccine production strategy involves ensuring that the vaccine strains"/>
 <result pre="to improve upon methods of monitoring and identifying newly evolved" exact="influenza" post="strains worldwide, including the incorporation of modeling techniques such"/>
 <result pre="is the major driving force behind the need to reformulate" exact="influenza" post="vaccines each year and poses a significant challenge for"/>
 <result pre="and poses a significant challenge for vaccine development. Furthermore, seasonal" exact="influenza" post="virus vaccines fail to provide protection against the novel"/>
 <result pre="with a lack of sufficient protection against seasonal and pandemic" exact="influenza" post="stains, the National Institute of Allergy and Infectious Diseases"/>
 <result pre="Infectious Diseases (NIAID) has prioritized the development of a universal" exact="influenza" post="vaccine that can afford protection against a broad variety"/>
 <result pre="vaccine that can afford protection against a broad variety of" exact="influenza" post="viruses (Erbelding et al., 2018). Currently, the majority of"/>
 <result pre="viruses (Erbelding et al., 2018). Currently, the majority of universal" exact="influenza" post="vaccine research efforts are aimed at inducing immunity against"/>
 <result pre="at inducing immunity against the highly conserved regions on the" exact="influenza" post="surface proteins or internal proteins of influenza viruses as"/>
 <result pre="regions on the influenza surface proteins or internal proteins of" exact="influenza" post="viruses as means to induce universal protection against all"/>
 <result pre="influenza viruses as means to induce universal protection against all" exact="influenza" post="virus strains (Figure 1). Figure 1 A schematic representation"/>
 <result pre="A schematic representation of various preclinical approaches for a universal" exact="influenza" post="vaccine. Universal Influenza Vaccine Approaches Hemagglutinin-Directed The influenza virus"/>
 <result pre="a universal influenza vaccine. Universal Influenza Vaccine Approaches Hemagglutinin-Directed The" exact="influenza" post="virus surface protein HA is one of the major"/>
 <result pre="than HA2 and displays a high degree of variability among" exact="influenza" post="virus strains. Conversely, the HA2 region is highly conserved"/>
 <result pre="strains. Conversely, the HA2 region is highly conserved among different" exact="influenza" post="virus subtypes and is more structurally constrained in its"/>
 <result pre="resulting antigenic drift is the major reason for reformulating seasonal" exact="influenza" post="vaccines with new strains every year. To address this"/>
 <result pre="vaccines still fall short of serving as a true universal" exact="influenza" post="vaccine. To generate broadly protective immune responses against multiple"/>
 <result pre="influenza vaccine. To generate broadly protective immune responses against multiple" exact="influenza" post="virus strains, several research groups developing universal influenza vaccines"/>
 <result pre="against multiple influenza virus strains, several research groups developing universal" exact="influenza" post="vaccines have targeted the highly conserved stalk domain of"/>
 <result pre="domain have been shown to provide cross-reactive protection against multiple" exact="influenza" post="virus strains (Throsby et al., 2008; Sui et al.,"/>
 <result pre="nanoparticle-based approaches provided cross-reactive protection following viral challenge with different" exact="influenza" post="A virus strains (Kanekiyo et al., 2013; Yassine et"/>
 <result pre="to ferrets immunized with two doses of a seasonal trivalent" exact="influenza" post="vaccine, demonstrating improved protection elicited by the cHA vaccination"/>
 <result pre="the ability to provide protection against a broad range of" exact="influenza" post="virus strains within a given HA subtype is a"/>
 <result pre="approved seasonal vaccines, this still falls short of providing universal" exact="influenza" post="virus protection. Another important consideration involves providing protection for"/>
 <result pre="virus protection. Another important consideration involves providing protection for both" exact="influenza" post="A and B virus strains. While the HA stalk-directed"/>
 <result pre="While the HA stalk-directed approaches described above demonstrate protection against" exact="influenza" post="A viruses, protection against influenza B strains is not"/>
 <result pre="described above demonstrate protection against influenza A viruses, protection against" exact="influenza" post="B strains is not always addressed. A truly universal"/>
 <result pre="universal vaccine should be able to provide protection against both" exact="influenza" post="A and B strains. Therefore, current universal vaccine research"/>
 <result pre="of the need to elicit protection for both types of" exact="influenza" post="viruses. Antibodies targeting the HA stalk domain have been"/>
 <result pre="HA stalk domain have been shown to be protective against" exact="influenza" post="B strains, with the human monoclonal antibody CR9114 demonstrating"/>
 <result pre="monoclonal antibody CR9114 demonstrating protection against lethal challenge from both" exact="influenza" post="A and B strains (Dreyfus et al., 2012). Recently,"/>
 <result pre="approach was used in an attempt to generate a universal" exact="influenza" post="B vaccine that could provide protection against a wide"/>
 <result pre="vaccine that could provide protection against a wide range of" exact="influenza" post="B virus lineages (Sun et al., 2019). To generate"/>
 <result pre="B virus lineages (Sun et al., 2019). To generate the" exact="influenza" post="B mHA, the major antigenic sites were replaced with"/>
 <result pre="B mHA, the major antigenic sites were replaced with &quot;exotic�?" exact="influenza" post="A sequences (Sun et al., 2019). Immunization of mice"/>
 <result pre="boosts (Sun et al., 2019). Importantly, mice vaccinated with the" exact="influenza" post="B mHA demonstrated improved survival following lethal challenge with"/>
 <result pre="B mHA demonstrated improved survival following lethal challenge with different" exact="influenza" post="B strains (Sun et al., 2019). While this study"/>
 <result pre="While this study does not provide evidence for protection against" exact="influenza" post="A strains, it further serves to highlight the potential"/>
 <result pre="vaccination strategies. It would be interesting to examine whether combining" exact="influenza" post="A mHAs and influenza B mHAs into a single"/>
 <result pre="be interesting to examine whether combining influenza A mHAs and" exact="influenza" post="B mHAs into a single vaccine might provide even"/>
 <result pre="a single vaccine might provide even greater protection for both" exact="influenza" post="A and B strains than the current inactivated quadrivalent"/>
 <result pre="inactivated quadrivalent vaccine. Neuraminidase-Directed The second major surface protein for" exact="influenza" post="A virus is the NA protein, which has an"/>
 <result pre="the enzymatic activity of NA and are effective against both" exact="influenza" post="A and B virus strains. Mutations that render NA"/>
 <result pre="candidates developed that target NA in order to generate improved" exact="influenza" post="vaccines. Unlike HA antibodies, NA antibodies do not neutralize"/>
 <result pre="as well as hemagglutinin inhibition titers as a measure of" exact="influenza" post="disease severity, suggesting that NA-based protection should be an"/>
 <result pre="NA-based protection should be an important consideration when developing new" exact="influenza" post="vaccines (Monto et al., 2015; Memoli et al., 2016)."/>
 <result pre="al., 2015; Job et al., 2018). Recently, a recombinant modified" exact="vaccinia virus" post="Ankara (MVA) vector was used to express either HA"/>
 <result pre="VLP vaccine has the potential to confer protection against different" exact="influenza" post="strains with different N1 subtype NAs (Kim et al.,"/>
 <result pre="Additional studies in animal models that more closely recapitulate human" exact="influenza" post="infection, like ferrets, are necessary to further examine the"/>
 <result pre="evidence for the importance of considering NA-based immune responses for" exact="influenza" post="vaccines. An important challenge in inducing NA directed immune"/>
 <result pre="subvert the HA immunodominance, a recent study generated two recombinant" exact="influenza" post="viruses based on the H1N1 stain A/Puerto Rico/8/1934 (PR8)"/>
 <result pre="protection in humans or models that more accurately reflect human" exact="influenza" post="virus infection are necessary to demonstrate the protection these"/>
 <result pre="can provide. M2 Ectodomain-Directed The third surface protein on the" exact="influenza" post="virion is the M2 protein. M2 is encoded by"/>
 <result pre="protein found on the virion membrane, is highly conserved among" exact="influenza" post="strains (Ito et al., 1991). Additionally, M2e-directed antibodies have"/>
 <result pre="et al., 1991). Additionally, M2e-directed antibodies have been detected during" exact="influenza" post="infection and have been shown to be protective in"/>
 <result pre="with M2e-directed antibodies, M2e has become a target for universal" exact="influenza" post="vaccine approaches. As with NA and the HA stalk,"/>
 <result pre="vaccines elicited M2 specific antibody responses and protected mice against" exact="influenza" post="A virus challenge, highlighting the importance of M2e mediated"/>
 <result pre="the importance of considering the M2e protein when formulating universal" exact="influenza" post="vaccines (Ionescu et al., 2006; Bessa et al., 2008;"/>
 <result pre="of T-cell responses, providing an additional layer of protection against" exact="influenza" post="viruses in the respiratory tract (Lee et al., 2019)."/>
 <result pre="limitation for this vaccination approach as is the breadth of" exact="influenza" post="strain protection. While M2e vaccination approaches may not provide"/>
 <result pre="enhance the immunogenicity and protection against a broader range of" exact="influenza" post="viruses. T-Cell-Directed In comparison to the surface glycoproteins of"/>
 <result pre="influenza viruses. T-Cell-Directed In comparison to the surface glycoproteins of" exact="influenza" post="virus, the internal proteins show higher degrees of conservation"/>
 <result pre="virus, the internal proteins show higher degrees of conservation among" exact="influenza" post="viruses and are often targeted by the antigen-specific CD8+"/>
 <result pre="lymphocytes. Given the importance of T cells in protection against" exact="influenza" post="virus infection, vaccines stimulating influenza specific T-cell immunity have"/>
 <result pre="T cells in protection against influenza virus infection, vaccines stimulating" exact="influenza" post="specific T-cell immunity have been explored as a promising"/>
 <result pre="immunity have been explored as a promising avenue for improving" exact="influenza" post="vaccine efficacy and developing a universal influenza vaccine. Most"/>
 <result pre="avenue for improving influenza vaccine efficacy and developing a universal" exact="influenza" post="vaccine. Most T-cell-directed vaccine approaches involve targeting conserved internal"/>
 <result pre="influenza vaccine. Most T-cell-directed vaccine approaches involve targeting conserved internal" exact="influenza" post="proteins or other highly conserved epitopes that stimulate T-cell-mediated"/>
 <result pre="expressing one B-cell epitope and two T-cell epitopes from H3" exact="influenza" post="strains in the flagellin of the Salmonella vaccine strain"/>
 <result pre="T-cell reactive regions by analyzing sequences from human and zoonotic" exact="influenza" post="A and B viral proteins (Stoloff and Caparros-Wanderley, 2007)."/>
 <result pre="regions, with M2 and PB1 sharing conserved sequences in both" exact="influenza" post="A and B isolates (Stoloff and Caparros-Wanderley, 2007). Mice"/>
 <result pre="not determine whether the vaccine provides protection against challenge with" exact="influenza" post="B infection, it does further demonstrate the importance of"/>
 <result pre="importance of stimulating CD8+ T cells to generate protection against" exact="influenza" post="infection. This vaccine is currently undergoing phase 2 clinical"/>
 <result pre="of nine conserved epitopes of HA, NP, and M1 from" exact="influenza" post="A and B viruses (Atsmon et al., 2012). Healthy"/>
 <result pre="other vaccine approaches, there have been attempts to generate T-cell-based" exact="influenza" post="vaccines through the use of viral vectors. One approach"/>
 <result pre="currently in clinical trials involves the use of a modified" exact="vaccinia virus" post="Ankara (MVA) that encodes influenza proteins NP and M1"/>
 <result pre="use of a modified vaccinia virus Ankara (MVA) that encodes" exact="influenza" post="proteins NP and M1 (MVA – NP + M1)"/>
 <result pre="these studies illustrate the importance of stimulating T-cell-based immunity for" exact="influenza" post="virus protection. Challenges to Universal Vaccine Development An important"/>
 <result pre="vaccine development involves defining the criteria for a successful universal" exact="influenza" post="vaccine. Would a universal vaccine provide protection against all"/>
 <result pre="influenza vaccine. Would a universal vaccine provide protection against all" exact="influenza" post="A and B strains? Only influenza A or B?"/>
 <result pre="provide protection against all influenza A and B strains? Only" exact="influenza" post="A or B? Or would the vaccine only provide"/>
 <result pre="approaches described above demonstrate novel methods of improving protection against" exact="influenza" post="virus infection, a concern that is often overlooked involves"/>
 <result pre="degree to which pre-existing immunity impacts the antibody response to" exact="influenza" post="infection and vaccination. This is true for all of"/>
 <result pre="referred to as &quot;original antigenic sin,�? suggests that the first" exact="influenza" post="virus variant an individual encounters impacts the immune response"/>
 <result pre="variant an individual encounters impacts the immune response to subsequent" exact="influenza" post="virus variants (Henry et al., 2018). While controversial, the"/>
 <result pre="(Henry et al., 2018). While controversial, the concept that previous" exact="influenza" post="virus exposure impacts antibody responses to influenza vaccination remains"/>
 <result pre="concept that previous influenza virus exposure impacts antibody responses to" exact="influenza" post="vaccination remains an important consideration for vaccine development (Henry"/>
 <result pre="approaches are done in naïve animals that lack any previous" exact="influenza" post="virus exposure. While unavoidable, this serves to highlight the"/>
 <result pre="vaccination remains the most efficient method to provide protection against" exact="influenza" post="virus infection, there is also significant interest in developing"/>
 <result pre="more broadly protective therapeutic methods for prevention and treatment of" exact="influenza" post="virus infection. A growing area of interest involves utilizing"/>
 <result pre="of interest involves utilizing broadly neutralizing antibodies to protect against" exact="influenza" post="virus infection. As with influenza vaccines, a significant focus"/>
 <result pre="neutralizing antibodies to protect against influenza virus infection. As with" exact="influenza" post="vaccines, a significant focus on broadly neutralizing antibody research"/>
 <result pre="particular antibodies that neutralize both Group 1 and Group 2" exact="influenza" post="virus HAs. Despite the fact that the majority of"/>
 <result pre="example, one study was able to identify four broadly neutralizing" exact="influenza" post="A antibodies through the activation and enrichment of human"/>
 <result pre="were able to neutralize both Group 1 and Group 2" exact="influenza" post="A viruses while also improving the survival of mice"/>
 <result pre="administered post infection, VIS401-treated mice showed reduced clinical symptoms of" exact="influenza" post="virus infection, including decreased viral spread and reduced damage"/>
 <result pre="treatment improved survival of mice and protected against several different" exact="influenza" post="A virus strains (Kallewaard et al., 2016). Similar results"/>
 <result pre="for utilizing broadly neutralizing antibodies to improve clinical outcomes of" exact="influenza" post="virus infection. Conclusions Significant resources have been invested into"/>
 <result pre="Significant resources have been invested into the development of universal" exact="influenza" post="virus vaccines and improved therapeutics for the treatment of"/>
 <result pre="influenza virus vaccines and improved therapeutics for the treatment of" exact="influenza" post="virus infection. Many universal influenza virus vaccine candidates focus"/>
 <result pre="therapeutics for the treatment of influenza virus infection. Many universal" exact="influenza" post="virus vaccine candidates focus on targeting conserved epitopes of"/>
 <result pre="on targeting conserved epitopes of influenza, including either the three" exact="influenza" post="surface proteins or highly conserved internal proteins. In doing"/>
 <result pre="approaches attempt to elicit broader protection against several strains of" exact="influenza" post="as opposed to the strain-specific protection provided by current"/>
 <result pre="as opposed to the strain-specific protection provided by current seasonal" exact="influenza" post="vaccines. In attempting to generate a truly universal vaccine,"/>
 <result pre="a truly universal vaccine, which would offer protection against all" exact="influenza" post="strains, these approaches have also highlighted innovative methods for"/>
 <result pre="vaccination approaches. By providing protection for a broader range of" exact="influenza" post="strains, these approaches have the potential to reduce the"/>
 <result pre="potential to reduce the need for yearly vaccine reformulations. While" exact="influenza" post="strains should still be closely monitored, broader protection against"/>
 <result pre="strains should still be closely monitored, broader protection against more" exact="influenza" post="strains could aid in improving yearly vaccine efficacy. The"/>
 <result pre="can offer in preventing and improving disease outcomes associated with" exact="influenza" post="virus infection. Additionally, these studies have provided an insight"/>
 <result pre="broadly neutralizing antibodies with current antivirals to improve recovery from" exact="influenza" post="virus infection (Nakamura et al., 2013; Tharakaraman et al.,"/>
 <result pre="2019). While the ultimate goal of developing a truly universal" exact="influenza" post="virus vaccine has yet to be achieved, the progress"/>
 <result pre="shows the exciting promise of these new approaches for improving" exact="influenza" post="disease outcomes and as well as the public health"/>
 <result pre="as the public health burden associated with inefficient protection against" exact="influenza" post="virus infection. Author Contributions All authors listed have made"/>
 <result pre="AinaiA.TamuraS.SuzukiT.van RietE.ItoR.OdagiriT.et al. (2013). Intranasal vaccination with an inactivated whole" exact="influenza" post="virus vaccine induces strong antibody responses in serum and"/>
 <result pre="inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2" exact="influenza" post="viruses. PLoS One13:e0204284. 10.1371/journal.pone.0210043, PMID: 30265682 AmbroseC. S.BrightH.MalloryR. (2016)."/>
 <result pre="the editor: potential causes of the decreased effectiveness of the" exact="influenza" post="A(H1N1)pdm09 strain in live attenuated influenza vaccines. Euro Surveill.21,"/>
 <result pre="decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated" exact="influenza" post="vaccines. Euro Surveill.21, pii: 30394. 10.2807/1560-7917.ES.2016.21.45.30394, PMID: 27918259 AmpofoW."/>
 <result pre="10.2807/1560-7917.ES.2016.21.45.30394, PMID: 27918259 AmpofoW. K.Azziz-BaumgartnerE.BashirU.CoxN. J.FasceR.GiovanniM.et al.. (2015). Strengthening the" exact="influenza" post="vaccine virus selection and development process: report of the"/>
 <result pre="process: report of the 3rd WHO informal consultation for improving" exact="influenza" post="vaccine virus selection held at WHO headquarters, Geneva, Switzerland,"/>
 <result pre="Vaccine33, 4368–4382. 10.1016/j.vaccine.2015.06.090, PMID: 26148877 AsahiY.YoshikawaT.WatanabeI.IwasakiT.HasegawaH.SatoY.et al.. (2002). Protection against" exact="influenza" post="virus infection in polymeric Ig receptor knockout mice immunized"/>
 <result pre="Y.et al.. (2012). Safety and immunogenicity of multimeric-001--a novel universal" exact="influenza" post="vaccine. J. Clin. Immunol.32, 595–603. 10.1007/s10875-011-9632-5, PMID: 22318394 BaranovichT.JonesJ."/>
 <result pre="E.et al.. (2016). The Hemagglutinin stem-binding monoclonal antibody VIS410 controls" exact="influenza" post="virus-induced acute respiratory distress syndrome. Antimicrob. Agents Chemother.60, 2118–2131."/>
 <result pre="(2016). The Hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced" exact="acute respiratory distress syndrome." post="Antimicrob. Agents Chemother.60, 2118–2131. 10.1128/AAC.02457-15, PMID: 26787699 BarrI. G.DonisR."/>
 <result pre="26787699 BarrI. G.DonisR. O.KatzJ. M.McCauleyJ. W.OdagiriT.TrusheimH.et al.. (2018). Cell culture-derived" exact="influenza" post="vaccines in the severe 2017–2018 epidemic season: a step"/>
 <result pre="in the severe 2017–2018 epidemic season: a step towards improved" exact="influenza" post="vaccine effectiveness. NPJ Vaccines3, 1–5. 10.1038/s41541-018-0079-z, PMID: 29354293 BelzG."/>
 <result pre="1–5. 10.1038/s41541-018-0079-z, PMID: 29354293 BelzG. T.WodarzD.DiazG.NowakM. A.DohertyP. C. (2002). Compromised" exact="influenza" post="virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J. Virol.76, 12388–12393."/>
 <result pre="Intranasal administration of peptide vaccine protects human/mouse radiation chimera from" exact="influenza" post="infection. Int. Immunol.11, 1043–1051. 10.1093/intimm/11.7.1043, PMID: 10383936 BernsteinD. I.GuptillJ.NaficyA.NachbagauerR.Berlanda-ScorzaF.FeserJ.et"/>
 <result pre="10383936 BernsteinD. I.GuptillJ.NaficyA.NachbagauerR.Berlanda-ScorzaF.FeserJ.et al. (2019). Immunogenicity of chimeric haemagglutinin-based, universal" exact="influenza" post="virus vaccine candidates: interim results of a randomised, placebo-controlled,"/>
 <result pre="Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic" exact="influenza" post="A vaccine, MVA-NP+M1. Clin. Infect. Dis.52, 1–7. 10.1093/cid/ciq015, PMID:"/>
 <result pre="D.KendalA. P. (1993). Antibody response to the M2 protein of" exact="influenza" post="A virus expressed in insect cells. J. Gen. Virol.74,"/>
 <result pre="8423445 BroeckerF.LiuS. T. H.SuntronwongN.SunW.BaileyM. J.NachbagauerR.et al. (2019a). A mosaic hemagglutinin-based" exact="influenza" post="virus vaccine candidate protects mice from challenge with divergent"/>
 <result pre="J.KrammerF.et al. (2019b). Extending the stalk enhances immunogenicity of the" exact="influenza" post="virus neuraminidase. J. Virol.93, 1–12. 10.1128/JVI.00840-19 BulloughP. A.HughsonF. M.SkehelJ."/>
 <result pre="1–12. 10.1128/JVI.00840-19 BulloughP. A.HughsonF. M.SkehelJ. J.WileyD. C. (1994). Structure of" exact="influenza" post="haemagglutinin at the pH of membrane fusion. Nature371, 37–43."/>
 <result pre="of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1" exact="influenza" post="viruses. J. Virol.90, 4720–4734. 10.1128/JVI.03152-15, PMID: 26912624 ClementsM. L.BettsR."/>
 <result pre="nasal wash antibodies associated with resistance to experimental challenge with" exact="influenza" post="A wild-type virus. J. Clin. Microbiol.24, 157–160. 10.1128/JCM.24.1.157-160.1986, PMID:"/>
 <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutinins. Science333, 850–856. 10.1126/science.1205669, PMID: 21798894 CoxM. M.HollisterJ."/>
 <result pre="PMID: 21798894 CoxM. M.HollisterJ. R. (2009). FluBlok, a next generation" exact="influenza" post="vaccine manufactured in insect cells. Biologicals37, 182–189. 10.1016/j.biologicals.2009.02.014, PMID:"/>
 <result pre="al.. (2005). Epidemiologic profile of a new H3N2 variant of" exact="influenza" post="A mismatched to vaccine, 2003-2004 influenza season. Can. Commun."/>
 <result pre="new H3N2 variant of influenza A mismatched to vaccine, 2003-2004" exact="influenza" post="season. Can. Commun. Dis. Rep.31, 21–31. Available at: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2005-31/epidemiologic-profile-a-new-h3n2-variant-influenza-a-mismatched-vaccine-2003-2004-influenza-season.html."/>
 <result pre="PMID: 15693177 DenisJ.Acosta-RamirezE.ZhaoY.HamelinM. E.KoukavicaI.BazM.et al.. (2008). Development of a universal" exact="influenza" post="A vaccine based on the M2e peptide fused to"/>
 <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against" exact="influenza" post="virus in vivo. Nat. Med.20, 143–151. 10.1038/nm.3443, PMID: 24412922"/>
 <result pre="DreyfusC.LaursenN. S.KwaksT.ZuijdgeestD.KhayatR.EkiertD. C.et al.. (2012). Highly conserved protective epitopes on" exact="influenza" post="B viruses. Science337, 1343–1348. 10.1126/science.1222908, PMID: 22878502 EasterbrookJ. D.SchwartzmanL."/>
 <result pre="M.GaoJ.KashJ. C.MorensD. M.CouzensL.et al.. (2012). Protection against a lethal H5N1" exact="influenza" post="challenge by intranasal immunization with virus-like particles containing 2009"/>
 <result pre="A.FriesenR. H.JongeneelenM.ThrosbyM.et al.. (2009). Antibody recognition of a highly conserved" exact="influenza" post="virus epitope. Science324, 246–251. 10.1126/science.1171491, PMID: 19251591 El BakkouriK.DescampsF.De"/>
 <result pre="Universal vaccine based on ectodomain of matrix protein 2 of" exact="influenza" post="A: Fc receptors and alveolar macrophages mediate protection. J."/>
 <result pre="ErbeldingE. J.PostD. J.StemmyE. J.RobertsP. C.AugustineA. D.FergusonS.et al.. (2018). A universal" exact="influenza" post="vaccine: the strategic plan for the National Institute of"/>
 <result pre="natural antibody are required in the long-term memory response to" exact="influenza" post="virus. Vaccine26(Suppl. 8), I86–I93. 10.1016/j.vaccine.2008.11.05719388171 FieldsB. N.KnipeD. M.HowleyP. M."/>
 <result pre="Philadelphia: Lippincott-Raven Publishers. GerdilC. (2003). The annual production cycle for" exact="influenza" post="vaccine. Vaccine21, 1776–1779. 10.1016/S0264-410X(03)00071-9, PMID: 12686093 GilesB. M.CrevarC. J.CarterD."/>
 <result pre="protective epitope that is highly conserved among human and nonhuman" exact="influenza" post="A viruses. Proc. Natl. Acad. Sci. USA107, 12658–12663. 10.1073/pnas.0911806107,"/>
 <result pre="10.1073/pnas.0911806107, PMID: 20615945 GravesP. N.SchulmanJ. L.YoungJ. F.PaleseP. (1983). Preparation of" exact="influenza" post="virus subviral particles lacking the HA1 subunit of hemagglutinin:"/>
 <result pre="J.KarronR. A.JerniganD. B.et al.. (2016). Prevention and control of seasonal" exact="influenza" post="with vaccines. MMWR Recomm. Rep.65, 1–54. 10.15585/mmwr.rr6505a1, PMID: 27560619"/>
 <result pre="B.BreseeJ. S.FryA. M.et al.. (2017). Prevention and control of seasonal" exact="influenza" post="with vaccines: recommendations of the advisory committee on immunization"/>
 <result pre="the advisory committee on immunization practices — United States, 2017–18" exact="influenza" post="season. MMWR Recomm. Rep.66, 1–20. 10.15585/mmwr.rr6602a1, PMID: 28841201 GrohskopfL."/>
 <result pre="Update: ACIP recommendations for the use of quadrivalent live attenuated" exact="influenza" post="vaccine (LAIV4) - United States, 2018-19 influenza season. MMWR"/>
 <result pre="quadrivalent live attenuated influenza vaccine (LAIV4) - United States, 2018-19" exact="influenza" post="season. MMWR Morb. Mortal. Wkly Rep.67, 643–645. 10.15585/mmwr.mm6722a5, PMID:"/>
 <result pre="E.PiedraP. A.LonginiI. M.Jr.GaglaniM. J.SchmotzerB.FewlassC.et al.. (2007). Efficacy of trivalent, cold-adapted," exact="influenza" post="virus vaccine against influenza A (Fujian), a drift variant,"/>
 <result pre="al.. (2007). Efficacy of trivalent, cold-adapted, influenza virus vaccine against" exact="influenza" post="A (Fujian), a drift variant, during 2003-2004. Vaccine25, 4038–4045."/>
 <result pre="Multiple redundant effector mechanisms of CD8+ T cells protect against" exact="influenza" post="infection. J. Immunol.190, 296–306. 10.4049/jimmunol.120057123197262 HamadaH.Garcia-Hernandez MdeL.ReomeJ. B.MisraS. K.StruttT."/>
 <result pre="subset of CD8 T cells that can protect against lethal" exact="influenza" post="challenge. J. Immunol.182, 3469–3481. 10.4049/jimmunol.0801814, PMID: 19265125 HeX. S.HolmesT."/>
 <result pre="responses in children and adults receiving inactivated or live attenuated" exact="influenza" post="vaccines. J. Virol.80, 11756–11766. 10.1128/JVI.01460-06, PMID: 16971435 HeW.TanG. S.MullarkeyC."/>
 <result pre="plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against" exact="influenza" post="A virus. Proc. Natl. Acad. Sci. USA113, 11931–11936. 10.1073/pnas.1609316113,"/>
 <result pre="E.KrammerF.WilsonP. C. (2018). From original antigenic sin to the universal" exact="influenza" post="virus vaccine. Trends Immunol.39, 70–79. 10.1016/j.it.2017.08.003, PMID: 28867526 HoftD."/>
 <result pre="28867526 HoftD. F.BabusisE.WorkuS.SpencerC. T.LottenbachK.TruscottS. M.et al.. (2011). Live and inactivated" exact="influenza" post="vaccines induce similar humoral responses, but only live vaccines"/>
 <result pre="PMID: 21846636 ImpagliazzoA.MilderF.KuipersH.WagnerM. V.ZhuX.HoffmanR. M.et al.. (2015). A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogen. Science349, 1301–1306."/>
 <result pre="16315228 ItoT.GormanO. T.KawaokaY.BeanW. J.WebsterR. G. (1991). Evolutionary analysis of the" exact="influenza" post="A virus M gene with comparison of the M1"/>
 <result pre="5491–5498. 10.1128/JVI.65.10.5491-5498.1991, PMID: 1895397 IwasakiA.PillaiP. S. (2014). Innate immunity to" exact="influenza" post="virus infection. Nat. Rev. Immunol.14, 315–328. 10.1038/nri3665, PMID: 24762827"/>
 <result pre="PMID: 24762827 JobE. R.YsenbaertT.SmetA.ChristopoulouI.StrugnellT.OlooE. O.et al.. (2018). Broadened immunity against" exact="influenza" post="by vaccination with computationally designed influenza virus N1 neuraminidase"/>
 <result pre="(2018). Broadened immunity against influenza by vaccination with computationally designed" exact="influenza" post="virus N1 neuraminidase constructs. NPJ Vaccines3:55. 10.1038/s41541-018-0093-1, PMID: 30510776"/>
 <result pre="(2016). Vaccine-induced antibodies that neutralize group 1 and group 2" exact="influenza" post="A viruses. Cell166, 609–623. 10.1016/j.cell.2016.06.043, PMID: 27453470 KallenK. J.HeidenreichR.SchneeM.PetschB.SchlakeT.ThessA.et"/>
 <result pre="(2016). Structure and function analysis of an antibody recognizing all" exact="influenza" post="A subtypes. Cell166, 596–608. 10.1016/j.cell.2016.05.073, PMID: 27453466 KanekiyoM.EllisD.KingN. P."/>
 <result pre="30715361 KanekiyoM.WeiC. J.YassineH. M.McTamneyP. M.BoyingtonJ. C.WhittleJ. R.et al.. (2013). Self-assembling" exact="influenza" post="nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature499, 102–106."/>
 <result pre="Influenza M2 virus-like particle vaccination enhances protection in combination with" exact="avian influenza" post="HA VLPs. PLoS One14:e0216871. 10.1371/journal.pone.0216871, PMID: 31246961 KilbourneE. D.JohanssonB."/>
 <result pre="M2 virus-like particle vaccination enhances protection in combination with avian" exact="influenza" post="HA VLPs. PLoS One14:e0216871. 10.1371/journal.pone.0216871, PMID: 31246961 KilbourneE. D.JohanssonB."/>
 <result pre="D.JohanssonB. E.GrajowerB. (1990). Independent and disparate evolution in nature of" exact="influenza" post="A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad."/>
 <result pre="Neuraminidase expressing virus-like particle vaccine provides effective cross protection against" exact="influenza" post="virus. Virology535, 179–188. 10.1016/j.virol.2019.07.008, PMID: 31310875 KimM. C.SongJ. M.EunjoO.KwonY."/>
 <result pre="M2 extracellular domains confer improved cross-protection against various subtypes of" exact="influenza" post="virus. Mol. Ther.21, 485–492. 10.1038/mt.2012.246, PMID: 23247101 KnossowM.GaudierM.DouglasA.BarrereB.BizebardT.BarbeyC.et al.."/>
 <result pre="10.1038/mt.2012.246, PMID: 23247101 KnossowM.GaudierM.DouglasA.BarrereB.BizebardT.BarbeyC.et al.. (2002). Mechanism of neutralization of" exact="influenza" post="virus infectivity by antibodies. Virology302, 294–298. 10.1006/viro.2002.1625, PMID: 12441073"/>
 <result pre="antibodies. Virology302, 294–298. 10.1006/viro.2002.1625, PMID: 12441073 KrammerF.PicaN.HaiR.MargineI.PaleseP. (2013). Chimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk-specific antibodies. J."/>
 <result pre="6542–6550. 10.1128/JVI.00641-13, PMID: 23576508 LambY. N. (2019). Cell-based quadrivalent inactivated" exact="influenza" post="virus vaccine (flucelvax((R)) tetra/flucelvax quadrivalent((R))): a review in the"/>
 <result pre="E.WeiC. J.HuZ.GordonI. J.EnamaM. E.HendelC. S.et al.. (2011). DNA priming and" exact="influenza" post="vaccine immunogenicity: two phase 1 open label randomised clinical"/>
 <result pre="al.. (2019). Enhancing the cross protective efficacy of live attenuated" exact="influenza" post="virus vaccine by supplemented vaccination with M2 ectodomain virus-like"/>
 <result pre="al.. (2012). Preliminary assessment of the efficacy of a T-cell-based" exact="influenza" post="vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis.55, 19–25. 10.1093/cid/cis327,"/>
 <result pre="immunization with recombinant neuraminidase proteins of H5N1 and pandemic H1N1" exact="influenza" post="A viruses. J. Virol.89, 7224–7234. 10.1128/JVI.00585-15, PMID: 25948745 LiuW."/>
 <result pre="immunization with live-attenuated chimeric Hemagglutinin-based vaccines confers Heterosubtypic immunity against" exact="influenza" post="A viruses in a preclinical ferret model. Front. Immunol.10:756."/>
 <result pre="LukacherA. E.BracialeV. L.BracialeT. J. (1984). In vivo effector function of" exact="influenza" post="virus-specific cytotoxic T lymphocyte clones is highly specific. J."/>
 <result pre="(2019). Pre-existing anti-neuraminidase antibodies are associated with shortened duration of" exact="influenza" post="A (H1N1)pdm virus shedding and illness in naturally infected"/>
 <result pre="(2013). Hemagglutinin stalk-based universal vaccine constructs protect against group 2" exact="influenza" post="A viruses. J. Virol.87, 10435–10446. 10.1128/JVI.01715-13, PMID: 23903831 McKinstryK."/>
 <result pre="M.SellS.DuttonR. W.et al.. (2012). Memory CD4+ T cells protect against" exact="influenza" post="through multiple synergizing mechanisms. J. Clin. Invest.122, 2847–2856. 10.1172/JCI63689,"/>
 <result pre="antihemagglutinin and antineuraminidase antibodies as correlates of protection in an" exact="influenza" post="A/H1N1 virus healthy human challenge model. MBio7:e00417-16. 10.1128/mBio.00417-16, PMID:"/>
 <result pre="27094330 MesedaC. A.AtukoraleV.SotoJ.EichelbergerM. C.GaoJ.WangW.et al.. (2018). Immunogenicity and protection against" exact="influenza" post="H7N3 in mice by modified vaccinia virus ankara vectors"/>
 <result pre="Immunogenicity and protection against influenza H7N3 in mice by modified" exact="vaccinia virus" post="ankara vectors expressing influenza virus hemagglutinin or neuraminidase. Sci."/>
 <result pre="H7N3 in mice by modified vaccinia virus ankara vectors expressing" exact="influenza" post="virus hemagglutinin or neuraminidase. Sci. Rep.8:5364. 10.1038/s41598-018-23712-9, PMID: 29599502"/>
 <result pre="PMID: 29599502 MontoA. S.PetrieJ. G.CrossR. T.JohnsonE.LiuM.ZhongW.et al.. (2015). Antibody to" exact="influenza" post="virus neuraminidase: an independent correlate of protection. J. Infect."/>
 <result pre="Infect. Dis.212, 1191–1199. 10.1093/infdis/jiv195, PMID: 25858957 MozdzanowskaK.MaieseK.FurchnerM.GerhardW. (1999). Treatment of" exact="influenza" post="virus-infected SCID mice with nonneutralizing antibodies specific for the"/>
 <result pre="M. (1972). Association of serum anti-neuraminidase antibody with resistance to" exact="influenza" post="in man. N. Engl. J. Med.286, 1329–1332. 10.1056/NEJM197206222862502, PMID:"/>
 <result pre="live-attenuated prime, inactivated boost vaccination strategy with chimeric hemagglutinin-based universal" exact="influenza" post="virus vaccines provides protection in ferrets: a confirmatory study."/>
 <result pre="Vaccines6, 1–11. 10.3390/vaccines6030047 NachbagauerR.LiuW. C.ChoiA.WohlboldT. J.AtlasT.RajendranM.et al.. (2017). A universal" exact="influenza" post="virus vaccine candidate confers protection against pandemic H1N1 infection"/>
 <result pre="in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic" exact="influenza" post="A antibodies. Cell Host Microbe14, 93–103. 10.1016/j.chom.2013.06.004, PMID: 23870317"/>
 <result pre="Microbe14, 93–103. 10.1016/j.chom.2013.06.004, PMID: 23870317 NeirynckS.DerooT.SaelensX.VanlandschootP.JouW. M.FiersW. (1999). A universal" exact="influenza" post="A vaccine based on the extracellular domain of the"/>
 <result pre="(1993). A common neutralizing epitope conserved between the hemagglutinins of" exact="influenza" post="A virus H1 and H2 strains. J. Virol.67, 2552–2558."/>
 <result pre="Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infection. Nat. Biotechnol.30, 1210–1216. 10.1038/nbt.2436, PMID: 23159882"/>
 <result pre="al. (2012). Hemagglutinin stalk antibodies elicited by the 2009 pandemic" exact="influenza" post="virus as a mechanism for the extinction of seasonal"/>
 <result pre="H.NichollsJ. M.PereraP. Y.LichyJ. H.YamamotoM.et al.. (2009). Vaccinia virus-based multivalent H5N1" exact="avian influenza" post="vaccines adjuvanted with IL-15 confer sterile cross-clade protection in"/>
 <result pre="M.PereraP. Y.LichyJ. H.YamamotoM.et al.. (2009). Vaccinia virus-based multivalent H5N1 avian" exact="influenza" post="vaccines adjuvanted with IL-15 confer sterile cross-clade protection in"/>
 <result pre="19234203 PutriW.MuscatelloD. J.StockwellM. S.NewallA. T. (2018). Economic burden of seasonal" exact="influenza" post="in the United States. Vaccine36, 3960–3966. 10.1016/j.vaccine.2018.05.057, PMID: 29801998"/>
 <result pre="(2004). Role of IgA versus IgG in the control of" exact="influenza" post="viral infection in the murine respiratory tract. J. Immunol.173,"/>
 <result pre="PMID: 15265932 RobertsonC. A.DiazGranadosC. A.DeckerM. D.ChitA.MercerM.GreenbergD. P. (2016). Fluzone(R) high-dose" exact="influenza" post="vaccine. Expert Rev. Vaccines15, 1495–1505. 10.1080/14760584.2016.1254044, PMID: 27813430 RogersG."/>
 <result pre="S.SkehelJ. J.WilsonI. A.WileyD. C. (1983). Single amino acid substitutions in" exact="influenza" post="haemagglutinin change receptor binding specificity. Nature304, 76–78. 10.1038/304076a0, PMID:"/>
 <result pre="S.KendalA. P.NeromeK. (1990). Cocirculation of two distinct evolutionary lineages of" exact="influenza" post="type B virus since 1983. Virology175, 59–68. 10.1016/0042-6822(90)90186-U, PMID:"/>
 <result pre="Methods78, 163–169. 10.1016/S0166-0934(98)00174-8, PMID: 10204706 RottR.BechtH.OrlichM. (1974). The significance of" exact="influenza" post="virus neuraminidase in immunity. J. Gen. Virol.22, 35–41. 10.1099/0022-1317-22-1-35,"/>
 <result pre="SagawaH.OhshimaA.KatoI.OkunoY.IsegawaY. (1996). The immunological activity of a deletion mutant of" exact="influenza" post="virus haemagglutinin lacking the globular region. J. Gen. Virol.77,"/>
 <result pre="R.WaterfieldM. D.WhiteJ. M.et al. (1982). Changes in the conformation of" exact="influenza" post="virus hemagglutinin at the pH optimum of virus-mediated membrane"/>
 <result pre="968–972.6951181 SkowronskiD. M.JanjuaN. Z.De SerresG.SabaiducS.EshaghiA.DickinsonJ. A.et al.. (2014). Low 2012-13" exact="influenza" post="vaccine effectiveness associated with mutation in the egg-adapted H3N2"/>
 <result pre="SkowronskiD. M.MasaroC.KwindtT. L.MakA.PetricM.LiY.et al.. (2007). Estimating vaccine effectiveness against laboratory-confirmed" exact="influenza" post="using a sentinel physician network: results from the 2005-2006"/>
 <result pre="J. (2015). Influenza vaccination strategies: comparing inactivated and live attenuated" exact="influenza" post="vaccines. Vaccines3, 373–389. 10.3390/vaccines3020373, PMID: 26343192 StachyraA.Gora-SochackaA.SirkoA. (2014). DNA"/>
 <result pre="multi-epitope peptides identified in silico induce protective immunity against multiple" exact="influenza" post="serotypes. Eur. J. Immunol.37, 2441–2449. 10.1002/eji.200737254, PMID: 17668898 SuiJ.HwangW."/>
 <result pre="and functional bases for broad-spectrum neutralization of avian and human" exact="influenza" post="A viruses. Nat. Struct. Mol. Biol.16, 265–273. 10.1038/nsmb.1566, PMID:"/>
 <result pre="Biol.16, 265–273. 10.1038/nsmb.1566, PMID: 19234466 SunW.KirkpatrickE.ErmlerM.NachbagauerR.BroeckerF.KrammerF.et al.. (2019). Development of" exact="influenza" post="B universal vaccine candidates using the &quot;mosaic�? Hemagglutinin approach."/>
 <result pre="cells. PLoS One3:e3942. 10.1371/journal.pone.0003942, PMID: 19079604 TisaV.BarberisI.FaccioV.PaganinoC.TrucchiC.MartiniM.et al.. (2016). Quadrivalent" exact="influenza" post="vaccine: a new opportunity to reduce the influenza burden."/>
 <result pre="(2016). Quadrivalent influenza vaccine: a new opportunity to reduce the" exact="influenza" post="burden. J. Prev. Med. Hyg.57, E28–E33. 10.15167/2421-4248/jpmh2016.57.1.600, PMID: 27346937"/>
 <result pre="A.LiO. T. W.LiA.BullM.WaldmannT. A.PereraL. P.et al.. (2018). Protection by universal" exact="influenza" post="vaccine is mediated by memory CD4 T cells. Vaccine36,"/>
 <result pre="W.MokC. K.NichollsJ. M.GuanY.et al. (2014). IL-15 adjuvanted multivalent vaccinia-based universal" exact="influenza" post="vaccine requires CD4+ T cells for heterosubtypic protection. Proc."/>
 <result pre="antibodies demonstrate accessible HA2 epitopes in minor subpopulation of native" exact="influenza" post="virus haemagglutinin molecules. Arch. Virol.130, 45–56. 10.1007/BF01318995, PMID: 7684894"/>
 <result pre="PMID: 7684894 WebsterR. G.ReayP. A.LaverW. G. (1988). Protection against lethal" exact="influenza" post="with neuraminidase. Virology164, 230–237. 10.1016/0042-6822(88)90640-X, PMID: 2452514 WebsterR. G.SharpG."/>
 <result pre="PMID: 2452514 WebsterR. G.SharpG. B.ClaasE. C. (1995). Interspecies transmission of" exact="influenza" post="viruses. Am. J. Respir. Crit. Care Med.152, S25–S30. 10.1164/ajrccm/152.4_Pt_2.S25,"/>
 <result pre="J.WileyD. C. (1981). Structure of the haemagglutinin membrane glycoprotein of" exact="influenza" post="virus at 3 A resolution. Nature289, 366–373. 10.1038/289366a0, PMID:"/>
 <result pre="hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2" exact="influenza" post="virus cocirculating variants. J. Virol.91, 1–19. 10.1128/JVI.01581-17, PMID: 28978710"/>
 <result pre="(2019). Preventing an antigenically disruptive mutation in egg-based H3N2 seasonal" exact="influenza" post="vaccines by mutational incompatibility. Cell Host Microbe25, 836–844.e5. 10.1016/j.chom.2019.04.01331151913"/>
 <result pre="A structural explanation for the low effectiveness of the seasonal" exact="influenza" post="H3N2 vaccine. PLoS Pathog.13:e1006682. 10.1371/journal.ppat.1006682, PMID: 29059230 YapK. L.AdaG."/>
 <result pre="Transfer of specific cytotoxic T lymphocytes protects mice inoculated with" exact="influenza" post="virus. Nature273, 238–239. 10.1038/273238a0, PMID: 306072 YassineH. M.BoyingtonJ. C.McTamneyP."/>
 <result pre="C.McTamneyP. M.WeiC. J.KanekiyoM.KongW. P.et al.. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic" exact="influenza" post="protection. Nat. Med.21, 1065–1070. 10.1038/nm.3927, PMID: 26301691 ZebedeeS. L.LambR."/>
 <result pre="15890902 ZostS. J.ParkhouseK.GuminaM. E.KimK.Diaz PerezS.WilsonP. C.et al.. (2017). Contemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
</results>
